LACTOLOGY FOUNDATION

Etilamfetamine (ATC A08AA06): Toxicological and Lactation Monograph

ATC class and general pharmacology

ATC code A08AA06 designates etilamfetamine (also known as ethylamphetamine or N-ethylamphetamine). It is classified in ATC group A08, anti-obesity preparations, excluding diet products, and subgroup A08AA, centrally acting anti-obesity products. The WHO ATC/DDD Index lists etilamfetamine as the substance assigned to A08AA06.atcddd.fhi+2

Etilamfetamine is an amphetamine-family sympathomimetic stimulant that was historically used as an anorectic agent for short-term appetite suppression in obesity management. Like other centrally acting anorectic stimulants, it does not treat the underlying causes of obesity and is not an appropriate substitute for sustained dietary, behavioural, physical-activity, and medical interventions. Its benefit is limited by tolerance and by clinically relevant cardiovascular, psychiatric, neurological, and dependence-related risks.pmc.ncbi.nlm.nih+1

Its central pharmacology is expected to resemble that of amphetamine-type stimulants. These compounds increase monoaminergic signalling—predominantly norepinephrine and dopamine, and variably serotonin depending on the individual agent—within central pathways that regulate appetite, arousal, reward, attention, and autonomic activity. The resulting appetite suppression occurs alongside stimulant effects such as increased wakefulness, reduced fatigue, sympathetic activation, and potential mood or behavioural change. Amphetamine-type stimulants primarily promote catecholamine release, although mechanistic effects can vary substantially between individual derivatives.scielo+1

Etilamfetamine is metabolically relevant because it can undergo N-dealkylation to amphetamine. Available data indicate that approximately 5–18% may be excreted in urine as amphetamine within 24 hours. Therefore, both the parent medicine and an active amphetamine metabolite may contribute to clinical effects, toxicity, and any potential exposure of a breastfed infant.wikipedia

Toxicological profile

The toxicological profile of etilamfetamine is consistent with an amphetamine-type stimulant. Important risks include central nervous system stimulation, sympathomimetic cardiovascular effects, sleep disturbance, psychiatric adverse effects, tolerance, and potential misuse or dependence. The magnitude of risk is influenced by dose, formulation, duration of use, individual susceptibility, cardiovascular and psychiatric comorbidity, co-exposures, and the possibility of active amphetamine metabolite formation.pmc.ncbi.nlm.nih+2

Common or expected adverse effects include:

• Insomnia, reduced sleep quality, restlessness, agitation, nervousness, anxiety, irritability, tremor, headache, and dizziness.
• Dry mouth, nausea, abdominal discomfort, constipation, reduced appetite beyond the intended therapeutic effect, and possible dehydration.
• Tachycardia, palpitations, elevation of blood pressure, peripheral vasoconstriction, and reduced exercise tolerance.
• Mood changes, dysphoria, behavioural disturbance, or exacerbation of pre-existing anxiety or mood disorders.

More severe toxicity may include marked hypertension, tachyarrhythmia, chest pain, hyperthermia, severe agitation, delirium, hallucinations, psychosis, seizures, stroke, myocardial infarction, rhabdomyolysis, and cardiovascular collapse. Such outcomes are particularly concerning after excessive doses, accidental ingestion by a child, non-medical use, or use with other stimulants, sympathomimetics, alcohol, or serotonergic medicines. Amphetamine-type substances have complex stimulant and monoaminergic actions; their high lipid solubility facilitates penetration of the blood–brain barrier and contributes to central toxicity.scielo+1

Etilamfetamine should be avoided in patients with significant cardiovascular disease, uncontrolled hypertension, tachyarrhythmia, hyperthyroidism, glaucoma, severe anxiety, agitation, psychosis, a history of stimulant misuse, or clinically important eating disorders. Use alongside monoamine oxidase inhibitors is potentially hazardous because of excessive catecholaminergic activity and the risk of severe hypertensive reactions. Concomitant exposure to other stimulants, decongestants, serotonergic agents, or illicit substances can further increase cardiovascular and neuropsychiatric toxicity.

Tolerance to anorectic effects may develop. Escalating the dose when appetite suppression diminishes is unsafe and may increase the risk of dependence and acute toxicity. Abrupt cessation after sustained high-dose stimulant exposure may be followed by fatigue, hypersomnia, depressed mood, increased appetite, dysphoria, and craving.

Lactation pharmacology and infant exposure

There are no adequate published lactation studies specific to etilamfetamine. No reliable human data define concentrations of etilamfetamine in breast milk, milk-to-plasma ratios, relative infant dose, infant serum concentrations, or infant developmental outcomes after exposure through breastfeeding. Consequently, a mazindol-style or amphetamine-style numerical exposure estimate cannot be validly extrapolated to etilamfetamine itself.

However, absence of etilamfetamine-specific measurements does not establish safety. Etilamfetamine is a small, centrally active, lipophilic amphetamine derivative. Amphetamine-type stimulants can cross biological membranes, including the blood–brain barrier and placenta, and may be secreted into breast milk. Its metabolism to amphetamine provides an additional reason for concern, since amphetamine itself has been measured in milk in other exposure contexts.scielo+1

In a small study of recreational intravenous methamphetamine exposure, both methamphetamine and amphetamine were measurable in milk, and investigators proposed a 48-hour withholding period after recreational use to reduce infant exposure. That evidence concerns methamphetamine exposure—not therapeutic etilamfetamine—and it must not be treated as a validated clearance interval for etilamfetamine. It nonetheless demonstrates that amphetamine-class compounds and metabolites can enter human milk and may expose a nursing infant.pmc.ncbi.nlm.nih+1

The potential effects of infant exposure are inferred from stimulant pharmacology rather than established etilamfetamine-specific case reports. Possible signs include:

• Irritability, unusual crying, restlessness, excessive wakefulness, or disrupted sleep.
• Poor latch, impaired suck, reduced feeding, vomiting, diarrhoea, or inadequate weight gain.
• Tachycardia, hypertension, pallor, sweating, tremor, or temperature instability.
• Excessive stimulation, altered muscle tone, or seizure-like activity in severe exposure.
• Reduced maternal milk production, particularly if treatment is started before lactation is well established or if maternal caloric intake and hydration are inadequate.

The neonatal period is the highest-risk stage because infants have immature hepatic metabolism, renal elimination, and autonomic reserve. Premature infants and infants with cardiac, neurological, hepatic, or renal disease may be particularly vulnerable. Product-specific caution is therefore warranted even though some therapeutic amphetamine data from other indications suggest that monitored use of certain amphetamine formulations may sometimes be managed differently. Those data cannot establish the safety of etilamfetamine, an anorectic stimulant with no direct breastfeeding evidence.drugs

Lactological safety assessment and clinical recommendations

Lactological safety assessment: Avoid during breastfeeding. Etilamfetamine should not be used as an anti-obesity medicine in a breastfeeding woman. This recommendation is based on the absence of direct milk and infant-safety data, its amphetamine-like central and cardiovascular toxicity, its potential to form amphetamine, possible transfer of stimulant compounds into milk, potential infant neurocardiovascular effects, and the fact that weight-loss pharmacotherapy is generally not an urgent maternal indication during lactation.pmc.ncbi.nlm.nih+2

Etilamfetamine should not be initiated for postpartum weight reduction while breastfeeding. The preferred approach is individualised, gradual postpartum weight management through a nutritionally adequate dietary pattern, physical activity appropriate to recovery and medical status, sleep and mental-health support, and assessment for endocrine, metabolic, or medication-related contributors to weight change. Aggressive caloric restriction and stimulant anorectics may also compromise maternal nutritional status, hydration, sleep, and the establishment or maintenance of milk production.

If maternal exposure has already occurred, the clinician should determine the exact product and formulation, dose, time of the most recent dose, frequency and duration of treatment, and whether other stimulants, decongestants, antidepressants, serotonergic drugs, alcohol, or illicit substances were used. The infant’s age, gestational age at birth, current health, feeding pattern, and presence of symptoms must also be assessed.

A definitive breastfeeding-interruption interval cannot be provided for etilamfetamine because direct human milk pharmacokinetic data are absent. The 48-hour withholding approach proposed after recreational methamphetamine exposure should not be presented as a validated rule for etilamfetamine, but may illustrate why prompt specialist advice is important after amphetamine-type stimulant exposure.pmc.ncbi.nlm.nih+1

For a single, unintentional exposure, management should be determined by a poison centre, clinical toxicologist, paediatrician, or lactation-medicine specialist. For repeated treatment, non-medical use, high-dose exposure, co-exposure to other stimulants or serotonergic drugs, or exposure of a premature or medically fragile infant, interruption of breastfeeding and use of an alternative feeding plan may be necessary while individual clinical advice is obtained.

The infant should receive urgent paediatric evaluation if any of the following occur:

• Poor feeding, repeated vomiting, dehydration, or reduced urine output.
• Marked irritability, persistent wakefulness, unusual somnolence, tremor, or abnormal movements.
• Rapid heartbeat, pallor, sweating, fever, breathing difficulty, or colour change.
• Seizure-like activity, reduced responsiveness, or failure to gain weight.

Clinical conclusion: etilamfetamine is not compatible with routine breastfeeding. Its historical use as a centrally acting anorectic, its amphetamine-like toxicology, its metabolism to amphetamine, and the absence of direct lactation evidence support avoidance and selection of non-stimulant, evidence-based postpartum weight-management strategies.atcddd.fhi+2